Global /United States /Healthcare /Drug Manufacturers - General /KALV

KalVista Pharmaceuticals, Inc.

KALV

• NASDAQ: KALV • Delayed

26.67USD 39%

As of 13 June 2026, KalVista Pharmaceuticals, Inc. has a market cap of $1.37B USD, ranking #8960 globally and #1954 in the United States. It ranks #759 in the Healthcare sector, and #285 in the Drug Manufacturers - General industry.

Global Rank

8960

Country Rank

1954

Sector Rank

759

Industry Rank

285

Key Stats

Market Cap

$1.37BUSD

Enterprise Value

$1.35BUSD

Revenue (TTM)

$73.62MUSD

EBITDA (TTM)

-$164.82MUSD

Net Income (TTM)

-$164.29MUSD

EBITDA Margin

-224%

Profit Margin

-223%

PS Ratio

18.6

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Benjamin Palleiko open_in_new

Employees

275

Website

kalvista.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
39%	36%	38%	76%	140%	65%	105%	213%	4%

Upcoming Earnings

Earnings Date

Thu, Jul 9

Earnings Time

sunny Before Open

EPS Estimate

-$0.4000

Revenue Estimate

$38.59M

News

KALV Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	KALV KalVista Pharmaceuticals Inc ISIN: US4834971032 Shares Out.: Shares Outstanding: 53.241M¹ Shares Float: 43.177M² TV: TradingView: NASDAQ: KALV SA: Stock Analysis: NASDAQ: KALV YF: Yahoo Finance: KALV GF: Google Finance: NASDAQ: KALV NQ: NASDAQ: KALV BA: Barron's: KALV MS: Morningstar: XNAS: KALV	26.67 USD	TV: TradingView: NASDAQ: KALV SA: Stock Analysis: NASDAQ: KALV YF: Yahoo Finance: KALV GF: Google Finance: NASDAQ: KALV NQ: NASDAQ: KALV BA: Barron's: KALV MS: Morningstar: XNAS: KALV
Frankfurt Stock Exchange (FRA) MIC: XFRA	4XC1 KalVista Pharmaceuticals Inc ISIN: US4834971032 TV: TradingView: FWB: 4XC1 SA: Stock Analysis: FRA: 4XC1 YF: Yahoo Finance: 4XC1.F GF: Google Finance: FRA: 4XC1 BA: Barron's: 4XC1 MS: Morningstar: XFRA: 4XC1	22.73 EUR	TV: TradingView: FWB: 4XC1 SA: Stock Analysis: FRA: 4XC1 YF: Yahoo Finance: 4XC1.F GF: Google Finance: FRA: 4XC1 BA: Barron's: 4XC1 MS: Morningstar: XFRA: 4XC1

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 56K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 40K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 26K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 20K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 11K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 9K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 23K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 21K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 20K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 13K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 8K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 8K%	14.6	United Kingdom

chevron_leftBack